VYNE Therapeutics to Participate in March Investor Conferences
VYNE Therapeutics (Nasdaq: VYNE), a clinical-stage biopharmaceutical company, has announced its management team's upcoming participation in two investor conferences scheduled for March. The company, which specializes in developing differentiated therapies for chronic inflammatory and immune-mediated conditions with high unmet need, will make these presentations available through webcasts.
The company has confirmed that webcast replays will be accessible on the VYNE website for a 90-day period following each event. This initiative demonstrates VYNE's commitment to maintaining transparency with investors and sharing updates about their development pipeline.
VYNE Therapeutics (Nasdaq: VYNE), un'azienda biofarmaceutica in fase clinica, ha annunciato la prossima partecipazione del suo team di gestione a due conferenze per investitori previste per marzo. L'azienda, specializzata nello sviluppo di terapie differenziate per condizioni infiammatorie croniche e mediate dal sistema immunitario con un elevato bisogno insoddisfatto, renderà disponibili queste presentazioni tramite webcast.
L'azienda ha confermato che le registrazioni dei webcast saranno accessibili sul sito web di VYNE per un periodo di 90 giorni dopo ciascun evento. Questa iniziativa dimostra l'impegno di VYNE a mantenere la trasparenza con gli investitori e a condividere aggiornamenti sul loro pipeline di sviluppo.
VYNE Therapeutics (Nasdaq: VYNE), una empresa biofarmacéutica en etapa clínica, ha anunciado la próxima participación de su equipo de gestión en dos conferencias para inversores programadas para marzo. La empresa, que se especializa en el desarrollo de terapias diferenciadas para condiciones inflamatorias crónicas y mediadas por el sistema inmunológico con una alta necesidad insatisfecha, hará que estas presentaciones estén disponibles a través de webcasts.
La empresa ha confirmado que las repeticiones de los webcasts estarán accesibles en el sitio web de VYNE durante un período de 90 días después de cada evento. Esta iniciativa demuestra el compromiso de VYNE con la transparencia hacia los inversores y la actualización sobre su pipeline de desarrollo.
VYNE Therapeutics (Nasdaq: VYNE)은 임상 단계의 생명공학 회사로, 3월에 예정된 두 개의 투자자 회의에 경영진 팀이 참여할 것이라고 발표했습니다. 만성 염증 및 면역 매개 질환에 대한 차별화된 치료법 개발을 전문으로 하는 이 회사는 이러한 발표를 웹캐스트를 통해 제공할 예정입니다.
회사는 각 이벤트 후 90일 동안 VYNE 웹사이트에서 웹캐스트 재생을 이용할 수 있다고 확인했습니다. 이 이니셔티브는 투자자와의 투명성을 유지하고 개발 파이프라인에 대한 업데이트를 공유하려는 VYNE의 의지를 보여줍니다.
VYNE Therapeutics (Nasdaq: VYNE), une entreprise biopharmaceutique en phase clinique, a annoncé la prochaine participation de son équipe de direction à deux conférences pour investisseurs prévues en mars. L'entreprise, spécialisée dans le développement de thérapies différenciées pour des conditions inflammatoires chroniques et médiées par le système immunitaire avec un fort besoin non satisfait, mettra ces présentations à disposition via des webcasts.
L'entreprise a confirmé que les rediffusions des webcasts seront accessibles sur le site web de VYNE pendant une période de 90 jours après chaque événement. Cette initiative démontre l'engagement de VYNE à maintenir la transparence envers les investisseurs et à partager des mises à jour concernant leur pipeline de développement.
VYNE Therapeutics (Nasdaq: VYNE), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die bevorstehende Teilnahme seines Managementteams an zwei Investorenkonferenzen im März angekündigt. Das Unternehmen, das sich auf die Entwicklung differenzierter Therapien für chronisch entzündliche und immunvermittelte Erkrankungen mit einem hohen ungedeckten Bedarf spezialisiert hat, wird diese Präsentationen über Webcasts verfügbar machen.
Das Unternehmen hat bestätigt, dass die Aufzeichnungen der Webcasts für einen Zeitraum von 90 Tagen nach jeder Veranstaltung auf der VYNE-Website zugänglich sein werden. Diese Initiative zeigt das Engagement von VYNE, Transparenz gegenüber den Investoren zu wahren und Updates über ihre Entwicklungs-Pipeline zu teilen.
- None.
- None.
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE’s management will participate in two investor conferences in March.
Details are as follows:
| TD Cowen 45th Annual Health Care Conference, Boston, MA | ||
| Conference Date: | March 4, 2025 | |
| Format: | Fireside chat and one-on-one meetings | |
| Fireside Chat Timing: | Tuesday, March 4, 2025, 11:10 AM ET | |
| Registration: | Webcast link | |
| Leerink Partners Global Healthcare Conference, Miami, FL | ||
| Conference Date: | March 11, 2025 | |
| Format: | One-on-one meetings | |
A webcast replay will be available on the VYNE website for 90 days following the event.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE’s unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission (“SEC”), public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@vynetx.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
FAQ
When will VYNE Therapeutics participate in the upcoming investor conferences?
How long will the VYNE conference webcasts be available for replay?
What is VYNE Therapeutics' current business focus?
Where can investors access VYNE's March 2025 conference presentations?
